Dr. Maria Bell, MD
Claim this profileSanford Cancer Center Oncology Clinic
Studies Ovarian Cancer
Studies Fallopian Tube Cancer
14 reported clinical trials
32 drugs studied
Area of expertise
1Ovarian Cancer
Stage IV
Stage III
Stage II
2Fallopian Tube Cancer
Stage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Maria Bell, MD is currently running
Risk-Based Screening
for Breast Cancer
Most physicians still use a one-size-fits-all approach to breast screening in which all women, regardless of their personal history, family history or genetics (except BRCA carriers) are recommended to have annual mammograms starting at age 40. Mammograms benefit women by detecting cancers early when they are easier to treat, but they are not perfect. Recent news stories have discussed some of the potential harms: large numbers of positive results that cause stressful recalls for additional mammograms and biopsies. With the current screening approach, half of the women who undergo annual screening for ten years will have at least one false positive biopsy. Potentially more important are cancer diagnoses for growths that might never come to clinical attention if left alone (called "overdiagnosis"). This can lead to unnecessary treatment. Even more concerning is evidence that up to 20% of breast cancers detected today may fall into the category of "overdiagnosis." The WISDOM 1.0 study compares annual screening with a risk-based breast cancer screening schedule, based upon each woman's personal risk of breast cancer. The investigators have designed the study to be inclusive of all, so that even women who might be nervous about being randomly assigned to receive a particular type of care (a procedure that is typical in clinical studies) will still be able to participate by choosing the type of care they receive. For participants in the risk-based screening arm, each woman will receive a personal risk assessment that includes her family and medical history, breast density measurement and tests for genes (mutations and variations) linked to the development of breast cancer. Women who have the highest personal risk of developing breast cancer will receive more frequent screening, while women with a lower personal risk would receive less frequent screening. No woman will be screened less than is recommended by the USPSTF breast cancer screening guidelines. If this study is successful, women will gain a realistic understanding of their personal risk of breast cancer as well as strategies to reduce their risk, and fewer women will suffer from the anxiety of false positive mammograms and unnecessary biopsies. The investigators believe this study has the potential to transform breast cancer screening in America. Starting in Spring 2023, WISDOM's design shifted to remove the randomized option, but will continue with the preference/self-selection option for participation (WISDOM 2.0). Participants will therefore continue to choose their study arm (Personalized or Annual) rather than have the option to be randomized. This study design change was made after review of the WISDOM 1.0 data by an independent monitoring committee, which indicates that personalized screening does not cause harm. WISDOM 2.0 has also lowered the eligibility to ages 30-74. Women ages 30-39 will only be offered to join the Personalized Arm.
Recruiting1 award N/A4 criteria
ACR-368
for Ovarian Cancer
This trial tests a new drug, ACR-368, alone or with a small dose of another drug, gemcitabine, in patients whose cancers don't respond to standard treatments. A special test helps decide which treatment might work best for each patient. Gemcitabine has been used with other drugs for various cancers, including pancreatic, lung, ovarian, and breast cancers.
Recruiting1 award Phase 210 criteria
More about Maria Bell, MD
Clinical Trial Related9 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Maria Bell, MD has experience with
- Paclitaxel
- Carboplatin
- External Beam Radiation Therapy
- Pembrolizumab
- Oregovomab
- Behavioral Dietary Intervention
Breakdown of trials Maria Bell, MD has run
Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Cancer
Endometrial Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Maria Bell, MD specialize in?
Maria Bell, MD focuses on Ovarian Cancer and Fallopian Tube Cancer. In particular, much of their work with Ovarian Cancer has involved Stage IV patients, or patients who are Stage III.
Is Maria Bell, MD currently recruiting for clinical trials?
Yes, Maria Bell, MD is currently recruiting for 5 clinical trials in Sioux Falls South Dakota. If you're interested in participating, you should apply.
Are there any treatments that Maria Bell, MD has studied deeply?
Yes, Maria Bell, MD has studied treatments such as Paclitaxel, Carboplatin, External Beam Radiation Therapy.
What is the best way to schedule an appointment with Maria Bell, MD?
Apply for one of the trials that Maria Bell, MD is conducting.
What is the office address of Maria Bell, MD?
The office of Maria Bell, MD is located at: Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota 57104 United States. This is the address for their practice at the Sanford Cancer Center Oncology Clinic.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.